ATYR1923 PULMONARY SARCOIDOSIS MULTIPLE ASCENDING DOSE TRIAL: PHASE 1b/2a
We are currently enrolling a Phase 1b/2a study evaluating our lead candidate, ATYR1923, in patients with pulmonary sarcoidosis.
This Phase 1b/2a study is a multiple-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate safety, tolerability and immunogenicity of multiple doses of ATYR1923, as well as to evaluate established clinical endpoints and potential biomarkers to assess preliminary efficacy in a hope for a sarcoidosis treatment.
Clinical Trial Information: This study is currently recruiting, if you are interested in participating please fill out the form below or email us at clinicaltrials@atyrpharma.com For more information about research centers open for recruitment near you, and to see whether you, or someone you know, qualifies to join the study, please fill out the form below or visit clinicaltrials.gov